Your health care provider should check your heart rate while you take Saxenda
Compliance and Legal Considerations GLP-1 coverage decisions introduce several compliance considerations
Amgens randomized, double-blind, placebo-controlled Phase II study enrolled 592 adults with obesity or overweight conditions, defined by a body mass index (BMI) of 30 or 27, respectively, with at least one obesity-related comorbidity
With compounding, providers can remove allergens, dyes, or fillers that cause issues
Oral arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men
Orlistat treatment should be continued beyond 12 weeks only if the person has lost at least 5% of their initial body weight